Última actualización 11 de julio de 2026
Key finding
More intervention than control participants achieved WL ≥15% at 52 weeks [51/201 (25.4%) vs 6/93 (6.5%); odds ratio 5.18; 95% CI 2.09, 12.88; p < 0.0001].
A study on liraglutide 3 mg demonstrated significant weight loss in adults with obesity compared to a control group.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
A study on liraglutide 3 mg demonstrated significant weight loss in adults with obesity compared to a control group.
These findings are clinically significant as they suggest that liraglutide 3 mg can be an effective option for weight management in adults with obesity. Given the rising prevalence of obesity-related health issues, effective treatments are crucial for improving patient outcomes and reducing healthcare costs associated with obesity.
The study had a high rate of adverse events in the liraglutide group. Findings may not be generalizable to populations outside the study sample. Long-term effects of liraglutide were not assessed beyond 52 weeks.
Published in
Publication details and source links for this paper.
Dimitris P, Werd A, Jonathan ZL, et al. A targeted prescribing pathway for liraglutide 3 mg improves weight loss in adults with obesity. The Lancet Regional Health - Europe. 2024;39:100853. doi:10.1016/j.lanepe.2024.100853
25.4% of liraglutide participants achieved weight loss ≥15% compared to 6.5% in the control group (odds ratio 5.18, p < 0.0001).
44.8% of liraglutide participants achieved weight loss ≥10% compared to 9.7% in the control group (odds ratio 8.1, p < 0.0001).
Weight change was -8.1 kg for the liraglutide group versus -2.7 kg for the control group (p < 0.0001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Liraglutide and Adverse events incidence, BMI, Body weight, and 4 more.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
7
Evidence pairs
321
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Liraglutide → Adverse events incidence
Liraglutide → Adverse events incidence
Liraglutide → Proportion of participants achieving weight loss of 15% or more at 52 weeks
Liraglutide → Proportion of participants achieving weight loss of 15% or more at 52 weeks
Liraglutide → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Liraglutide → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Liraglutide → Weight loss of 10% or more at 52 weeks
Liraglutide → Weight loss of 10% or more at 52 weeks
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and Body Mass Index.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Body Mass Index
Measures Body Mass Index as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
6 results
3 results
6 results
6 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.9 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Strong | EvidenceScore™ 75.9 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Composition.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Waist circumference
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Weight Loss Outcomes.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Proportion of participants achieving weight loss of 15% or more at 52 weeks
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Proportion of participants achieving weight loss of 5% or more at 52 weeks
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Weight loss of 10% or more at 52 weeks
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
